Guests who are currently booked on cancelled voyages on Norwegian Cruise Line, Oceania Cruises or Regent Seven Seas Cruises are asked to contact their travel advisor or the cruise line for more information.

About Norwegian Cruise Line Holdings Ltd.

Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) is a leading global cruise company which operates the Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands.  With a combined fleet of 28 ships with approximately 59,150 berths, these brands offer itineraries to more than 490 destinations worldwide. The Company will introduce nine additional ships through 2027.

Cautionary Statement Concerning Forward-Looking Statements

Some of the statements, estimates or projections contained in this release are “forward-looking statements” within the meaning of the U.S. federal securities laws intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this release, including, without limitation, those regarding our business strategy, financial position, results of operations, plans, prospects and objectives of management for future operations (including those regarding expected fleet additions, our voluntary suspension, our ability to weather the impacts of the COVID-19 pandemic, operational position, demand for voyages) are forward-looking statements. Many, but not all, of these statements can be found by looking for words like “expect,” “anticipate,” “goal,” “project,” “plan,” “believe,” “seek,” “will,” “may,” “forecast,” “estimate,” “intend,” “future” and similar words.

Forward-looking statements do not guarantee future performance and may involve risks, uncertainties and other factors which could cause our actual results, performance or achievements to differ materially from the future results, performance or achievements expressed or implied in those forward-looking statements.

Examples of these risks, uncertainties and other factors include, but are not limited to, the impact of: the spread of epidemics, pandemics and viral outbreaks and specifically, COVID-19, on our financial condition and operations, which adversely affects our ability to obtain acceptable financing in an amount equal to the resulting reduction in cash from operations, and the current, and uncertain future, other impacts of the COVID-19 outbreak, including its effect on the ability or desire of people to travel (including on cruises), which are expected to continue to adversely impact our results, operations, outlook, plans, goals, growth, reputation, cash flows, liquidity, demand for voyages and share price; our ability to develop strategies to enhance our health and safety protocols to adapt to the current pandemic environment’s unique challenges once operations resume and to otherwise safely resume our operations when conditions allow; coordination and cooperation with the CDC, the federal government and global public health authorities to take precautions to protect the health, safety and security of guests, crew and the communities visited and the implementation of any such precautions; the accuracy of any appraisals of our assets as a result of the impact of COVID-19 or otherwise; our success in reducing operating expenses and capital expenditures and the impact of any such reductions; our guests’ election to take cash refunds in lieu of future cruise credits or the continuation of any trends relating to such election; trends in, or changes to, future bookings and our ability to take future reservations and receive deposits related thereto; the unavailability of ports of call; future increases in the price of, or major changes or reduction in, commercial airline services; our ability to work with lenders and others or otherwise pursue options to defer or refinance our existing debt profile, near-term debt amortization, newbuild related payments and other obligations and to work with credit card processors to satisfy current or potential future demands for collateral on cash advanced from customers relating to future cruises; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; adverse incidents involving cruise ships; adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; our potential future need for additional financing, which may not be available on favorable terms, or at all, and may be dilutive to existing shareholders; any further impairment of our trademarks, trade names or goodwill; breaches in data security or other disturbances to our information technology and other networks or our actual or perceived failure to comply with requirements regarding data privacy and protection; changes in fuel prices and the type of fuel we are permitted to use and/or other cruise operating costs; mechanical malfunctions and repairs, delays in our shipbuilding program, maintenance and refurbishments and the consolidation of qualified shipyard facilities; the risks and increased costs associated with operating internationally; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our expansion into and investments in new markets; our inability to obtain adequate insurance coverage; our indebtedness and restrictions in the agreements governing our indebtedness that require us to maintain minimum levels of liquidity and otherwise limit our flexibility in operating our business, including the significant portion of assets that are collateral under these agreements; pending or threatened litigation, investigations and enforcement actions; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; our inability to recruit or retain qualified personnel or the loss of key personnel or employee relations issues; our reliance on third parties to provide hotel management services for certain ships and certain other services; our inability to keep pace with developments in technology; changes involving the tax and environmental regulatory regimes in which we operate; and other factors set forth under “Risk Factors” in our most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the Securities and Exchange Commission.

Additionally, many of these risks and uncertainties are currently amplified by and will continue to be amplified by, or in the future may be amplified by, the COVID-19 outbreak. It is not possible to predict or identify all such risks.

There may be additional risks that we consider immaterial or which are unknown. The above examples are not exhaustive and new risks emerge from time to time. Such forward-looking statements are based on our current beliefs, assumptions, expectations, estimates and projections regarding our present and future business strategies and the environment in which we expect to operate in the future. These forward-looking statements speak only as of the date made. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in our expectations with regard thereto or any change of events, conditions or circumstances on which any such statement was based, except as required by law.

“We are incredibly saddened by the loss of the visionary who not only brought our Company, but our industry, to life,” said Norwegian Cruise Line Holdings President and CEO Frank Del Rio. “Knut was a pioneer in our industry and certainly ahead of his time, exploring every opportunity to be at the forefront and break boundaries. His passion went beyond cruising with contributions to social, cultural, humanitarian and environmental causes worldwide.”

Kloster’s influence on the Company and the industry is profound. Starting in 1966, he tapped into America’s growing demand for international travel by offering roundtrip cruises from the then-nascent Port of Miami on the 550-passenger M/S Sunward, in the process creating the modern cruise industry we know today. His innovations continued, founding the industry’s first private island in Great Stirrup Cay and launching the industry’s first mega-ship in the Caribbean with the SS Norway.

Born in Oslo, Norway in 1929, Kloster became head of his family’s shipping company at an early age.  In an effort to diversify, he expanded operations to include a passenger ship to sail voyages in Gibraltar and Morocco which were complicated by geopolitical events in the region. He would receive a fortuitous communication from one Ted Arison, inviting him to come to Miami to inspect the facilities and perhaps reposition his M/S Sunward to the Caribbean. Norwegian Caribbean Lines was soon formed and in December 1966, the first voyage from Miami, FL to Nassau, the Bahamas departed, ushering in a new era of cruising.

Despite being a titan of the industry, he was most renowned for his extraordinary character; he espoused an unwavering belief that lasting commercial success rested in social and environmental responsibility as much as in financial accountability.

In addition to his deep appreciation and care for the environment, Kloster was a humanitarian. With crews hailing from multinational backgrounds, he developed a culture of inclusion and understanding on board his ships. For his efforts, he received permission from the United Nations to fly its flag atop SS Norway’s mast.

Del Rio added, “Knut Kloster’s legacy lives on throughout the cruise industry with every new vessel that is launched and every new innovation that is introduced. It is with great pride and a tremendous sense of responsibility, that we carry on with the vision he created many years ago. The design for the Pearl of Miami, our iconic, state-of-the-art terminal at PortMiami, took inspiration from the “white ships” that defined our Company’s growth in the late 1960s, so it is only fitting that we dedicate the main hall of the Pearl of Miami as Kloster Hall in his memory. Mr. Kloster’s biggest contribution to our Company and the industry was his penchant for innovation and I am proud to establish the Knut Kloster Team Member Award for Innovation, a $10,000 award to be presented annually to a shipside or shoreside team member who has consistently demonstrated our Company’s ideals of innovation.”

New recommendations from a panel of globally recognized medical and scientific experts say that by relentlessly focusing on prevention and other measures – including the testing of guests and crew members – public health risks associated with the pandemic can be mitigated in a cruise ship environment.

The Healthy Sail Panel submitted its recommendations today to the U.S. Centers for Disease Control and Prevention (CDC), in response to a CDC request for public comment that will be used to inform future public health guidance and preventative measures relating to travel on cruise ships. The Panel was formed in June by Royal Caribbean Group (NYSE: RCL) and Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH).

The Panel comprises globally recognized experts in medical practice and research, public health, infectious diseases, biosecurity, hospitality and maritime operations that have applied the best available public health, science and engineering insights to their recommendations.

The Healthy Sail Panel’s 65-plus-page report includes 74 detailed best practices to protect the public health and safety of guests, crew and the communities where cruise ships call. Recommendations include testing, the use of face coverings, and enhanced sanitation procedures on ships and in terminals. The Panel is chaired by Governor Mike Leavitt, former U.S. Secretary of Health and Human Services, and Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration.

“The Healthy Sail Panel spent the last four months studying how to better protect the health and safety of guests and crew aboard cruise ships,” said Dr. Gottlieb. “Taken as a comprehensive approach, we believe the Panel’s robust public health recommendations will help inform strategies for a safe resumption of sailing.”

Healthy Sail Panel Recommendations – Page 2

Gov. Leavitt said: “This Panel undertook an ambitious, cross-disciplinary, public health examination to develop standards and guidelines that create the highest level of safety in the complex environment of a cruise ship. We studied the industry’s experiences combating the pandemic – and we then incorporated the many lessons learned and advances made by medicine and science over the past six months. The Panel’s recommendations are grounded in the best scientific and medical information available and are intended to meaningfully mitigate public health risks to those who sail.”

“We understand our responsibility to act aggressively to protect the health and safety of our guests and crew, as well as the communities where we sail, and we asked the Panel to help us learn how to best live up to that responsibility,” said Richard D. Fain, chairman and CEO of Royal Caribbean Group. “We were inspired by the depth of the Panel’s work and their determination to help us establish the strongest protocols in the travel industry.”

“The Healthy Sail Panel’s recommendations are robust and comprehensive, and they reflect the intense focus the panelists brought to their work,” said Frank Del Rio, president and CEO of Norwegian Cruise Line Holdings Ltd. “We know that both authorities around the globe and consumers expect cruise lines to provide the safest, healthiest vacations we can, and this work demonstrates our commitment to doing just that.”

Fain and Del Rio said each company will use the Panel’s recommendations to inform the development of new, detailed operating protocols, which will be submitted to the CDC and other authorities around the globe for review and approval– an important milestone in the process of resuming sailing around the world. The Panel’s work is open sourced for others to incorporate in their protocols as well; Governor Leavitt and Dr. Gottlieb expressed appreciation that authorities and other cruise companies had already engaged in the Panel’s work as observers.

Healthy Sail Panel Recommendations – Page 3

The Healthy Sail Panel identified five areas of focus every cruise operator should address to improve health and safety for guests and crew, and reduce the risk of infection and spread of COVID-19 on cruise ships:

1. Testing, Screening and Exposure Reduction
2. Sanitation and Ventilation
3. Response, Contingency Planning and Execution
4. Destination and Excursion Planning
5. Mitigating Risks for Crew Members

In each category, the Healthy Sail Panel created practical and actionable recommendations to address specific safety concerns. Among the recommendations are key strategies such as:

• Taking aggressive measures to prevent SARS-CoV-2 from entering a ship through robust education, screening and testing of both crew and guests prior to embarkation
• Reducing transmission via air management strategies and enhanced sanitation practices
• Implementing detailed plans to address positive infection on board, including contingencies for onboard treatment, isolation and rapid evacuation and repatriation
• Closely controlling shore excursions
• Enhanced protection for crew members

The full Healthy Sail Panel report can be found here: Royal Caribbean Group or Norwegian Cruise Line Holdings Ltd.

Cruise industry leaders Royal Caribbean Group and Norwegian Cruise Line Holdings Ltd. announced a collaboration to develop enhanced cruise health and safety standards in response to the global COVID-19 pandemic.

The companies have asked Governor Mike Leavitt and Dr. Scott Gottlieb to serve as co-chairs of a newly formed group of experts called the “Healthy Sail Panel.” The panel is tasked with collaboratively developing recommendations for cruise lines to advance their public health response to COVID-19, improve safety, and achieve readiness for the safe resumption of operations.

The expert panel has been working for nearly a month and will offer its initial recommendations by the end of August. The cruise lines said its work will be “open source,” and could be freely adopted by any company or industry that would benefit from the group’s scientific and medical insights.

“This unprecedented disease requires us to develop unprecedented standards in health and safety,” said Richard D. Fain, chairman and CEO of Royal Caribbean Group. “Bringing aboard these respected experts to guide us forward demonstrates our commitment to protecting our guests, our crews and the communities we visit.”

“We compete for the vacationing consumer’s business every day, but we never compete on health and safety standards,” said Frank Del Rio, president and CEO of Norwegian Cruise Line Holdings Ltd. “While the cruise industry has always had rigorous health standards, the unique challenges posed by COVID-19 provide an opportunity to raise the bar even higher.”

“Health and safety are the highest priority for all CLIA cruise line members as demonstrated by this initiative on the part of two of our largest members. We commend this and parallel efforts of all of our members, large and small, who are working tirelessly to develop appropriate protocols based on input from health authorities and medical experts in the U.S. and abroad,” said Kelly Craighead, president and CEO of Cruise Lines International Association (CLIA).

Fain and Del Rio said they initiated the panel to assure the plans they will submit to the U.S. Centers for Disease Control and Prevention (CDC) and other regulators apply the best available public health, science and engineering insights. The work of the panel will be shared with the entire industry and regulators.

“In convening the Healthy Sail Panel, we sought the participation of a diverse group of leading experts in areas of science and public health that are directly relevant to the considerations listed by the No Sail Order,” said Governor Leavitt. “We view our work as a profoundly important public health effort. The health and safety of passengers, crew, and the communities that cruise ships visit will be the principal focus of this project.”

Dr. Gottlieb said, “We know that the public health issues that must be addressed are complex, and in some areas, tackling them will require novel approaches. Our goal in assembling this team of leading experts was to develop best practices that can improve safety and provide a roadmap for reducing the risks of COVID-19.”

The panel is co-chaired by Governor Leavitt, former Secretary of the U.S. Department Health and Human Services (HHS), and Dr. Scott Gottlieb, former commissioner of the U.S. Food and Drug Administration (FDA). The panel’s members are globally recognized experts from various disciplines, including public health, infectious disease, biosecurity, hospitality and maritime operations.

The members of the expert panel are:

Governor Mike Leavitt

Mike Leavitt was a three term Governor of Utah and served as Administrator of the EPA and Secretary of HHS under President George W. Bush. He is the founder of Leavitt Partners, a firm that provides investment support, data and analytics, member-based alliances, and direct services to clients to support decision-making strategies in the value economy.

Dr. Scott Gottlieb

Dr. Scott Gottlieb was the Commissioner of the FDA from 2017-2019 and served as the agency’s Deputy Commissioner for Medical and Scientific Affairs from 2005-2007. He is a physician trained in internal medicine and is currently a resident fellow at the American Enterprise Institute.

Helene Gayle MD, MPH

Dr. Gayle is CEO of the Chicago Community Trust, one of the nation’s leading community foundations. Prior to this role, foralmost a decade, she was president and CEO of CARE, a leading international humanitarian organization. An expert on global development, humanitarian and health issues, Dr. Gayle spent 20 years with the CDC, working primarily on HIV/AIDS. She worked at the Bill & Melinda Gates Foundation, directing programs on HIV/AIDS and other global health issues. She also launched the McKinsey Social Initiative (now McKinsey.org), a nonprofit that builds partnerships for social impact. Dr. Gayle serves on public company and nonprofit boards, including The Coca-Cola Company, Colgate-Palmolive Company, the Brookings Institution, the Center for Strategic and International Studies, New America, the ONE Campaign, the Federal Reserve Bank of Chicago and the Economic Club of Chicago. She is a member of the Council on Foreign Relations, the American Public Health Association, the National Academy of Medicine, the National Medical Association and the American Academy of Pediatrics.

Julie Gerberding, MD, MPH

Dr. Julie L. Gerberding is Executive Vice President and Chief Patient Officer for Merck, leading all aspects of strategic communications, global public policy, population health and patient engagement.

A former head of the CDC and a world-renowned public health expert, Dr. Gerberding is deeply committed to achieving sustainable global health impact and tackling some of the most challenging health priorities of our time. This includes addressing critical issues such as affordable access to important therapies, advocating for health policies that promote and sustain innovation of new medicines and vaccines, and improving maternal mortality through the Merck for Mothers program — a public-private partnership helping to meet the United Nations’ Sustainable Development Goal to reduce maternal mortality.

Prior to joining Merck, Dr. Gerberding served as the Director of the CDC from 2002-2009 and was the first female to hold that position. While at the agency, she led more than 40 emergency responses against crises such as anthrax, SARS, bird flu, food-borne outbreaks and natural disasters. Previously, Dr. Gerberding was a tenured faculty member in Infectious Diseases at the University of California at San Francisco (UCSF). She continues as an Adjunct Associate Clinical Professor of Medicine at UCSF.

Steven Hinrichs, MD

Dr. Steven Hinrichs is Professor and Chair in the Department of Pathology and Microbiology at the University of Nebraska Medical Center in Omaha and the Director of the Nebraska Public Health Laboratory (NPHL), and Director of the University of Nebraska Center for Biosecurity. In his position as laboratory director he has been responsible for the development of a statewide program for the rapid identification of biological agents of mass destruction. He is principal investigator of multiple national awards from the Association of Public Health Laboratories (APHL) and the CDC and the U.S. Department of Defense for the development of an outreach program to extend training and expertise in the early recognition of biological warfare agents. Dr. Hinrichs received his MD from the University of North Dakota and is board certified in Anatomical and Clinical Pathology. His research laboratory focuses on molecular diagnostics and the role of viruses in cancer. Dr. Hinrichs has published over 130 papers in basic science and medical journals.

Michael Osterholm, MD, PhD

Michael Osterholm is one of the nation’s foremost experts in public health, infectious disease and biosecurity. As the director of the Center for Infectious Disease Research and Policy at the University of Minnesota, he is an international leader on the world’s preparedness for pandemics. He has led numerous investigations into internationally important disease outbreaks, including foodborne diseases, hepatitis B in health care settings, and HIV infection in healthcare workers, and he is a frequent consultant to the World Health Organization, the National Institutes of Health, the FDA, the U.S. Department of Defense and the CDC. From 2001 to 2005, Dr. Osterholm served as a special advisor to the Secretary of HHS on issues related to bioterrorism and public health preparedness. From June 2018 through May 2019, he served as a Science Envoy for Health Security on behalf of the U.S. Department of State. He has also been appointed to the National Science Advisory Board on Biosecurity and the World Economic Forum’s Working Group on Pandemics, among other prominent advisory positions.

Stephen Ostroff, MD

Dr. Ostroff brings years of experience in public health, having served at high level positions at the FDA and CDC. He was the Acting Commissioner of the FDA from 2015-2016, and before that served as the FDA’s chief scientist. Ostroff joined the FDA in 2013 as chief medical officer in the Center for Food Safety and Applied Nutrition and senior public health advisor to FDA’s Office of Foods and Veterinary Medicine. Prior to that he served as deputy director of the National Center for Infectious Diseases at the CDC, where he was also acting director of CDC’s Select Agent Program. While at the CDC he focused on emerging infectious diseases, food safety, and coordination of complex outbreak response. He retired from the Commissioned Corps of the U.S. Public Health Service at the rank of Rear Admiral (Assistant Surgeon General). Ostroff was also the director of the Bureau of Epidemiology and acting physician general for the Commonwealth of Pennsylvania and has consulted internationally on public health projects in South Asia and Latin America. Ostroff graduated from the University of Pennsylvania School of Medicine in 1981 and completed residencies in internal medicine at the University of Colorado Health Sciences Center and preventive medicine at CDC.

William Rutala, PhD, MS, MPH

Dr. Rutala has experience medically managing a variety of diseases and extensive experience studying epidemiology and virology, particularly managing outbreaks and emerging pathogens. Dr. Rutala’s research interests are the etiology and prevention of healthcare-associated infections with a special focus on disinfection and sterilization of reusable medical and surgical devices (e.g., endoscopes, surgical instruments). Other areas of active research include contribution of the hospital environment to disease transmission, hand hygiene, preventing transmission of infectious agents, including multiply-drug resistant organisms, prevention of healthcare-associated Creutzfeldt-Jakob Disease, investigation of healthcare-associated outbreaks, and new and emerging pathogens in healthcare.

Kate Walsh, PhD

Kate Walsh is the Dean at the School of Hotel Administration at Cornell University and E.M. Statler Professor. A professor of management, she is a leader in education for the global hospitality industry; and a renowned expert in organizational service design, leadership and career development, as well as the impact of strategic human capital investments. In addition to authoring and contributing to books, Dr. Walsh’s articles have appeared in numerous research outlets. She has over 20 years of academic experience, including in her current role as dean.

In addition, Dean Walsh holds extensive industry knowledge from serving as the former director of training and development for Nikko Hotels International, corporate training manager for the former Bristol Hotels, and senior auditor for Loews Corporation. She is also a former New York State Certified Public Accountant. Since the beginning of her administration as dean, Dean Walsh has focused on positioning the school for the future of education. This includes undertaking a comprehensive renewal of the graduate and undergraduate curricula, developing the school’s online global presence, identifying international partners for master-level program development, and providing thought leadership for the hospitality industry, most notably through the creation of industry research partnerships for faculty, fostering new initiatives through the school’s six centers and institutes, and providing faculty-developed resources to guide the industry. Dr. Walsh received her Ph.D. from the Carroll School of Management at Boston College and her M.P.S. degree from Cornell’s School of Hotel Administration.

Captain Patrik Dahlgren

Captain Patrik Dahlgren is the Senior Vice President of Global Marine Operations and Fleet Optimization for all Royal Caribbean Group global brands. Dahlgren’s seagoing experiences started as a bridge officer aboard tugboats, yachts and an array of cargo vessels and ferries. He rose through the ranks with over 15 years onboard Royal Caribbean International cruise ships, with his last seagoing command as Master of Oasis of the Seas and Quantum of the Seas. He was a lead contributor to the Quantum of the Seas development and received the esteemed RINA (Royal Institute of Naval Architects) award for its innovation and contributions to maritime safety.

Robin Lindsay

Robin Lindsay is the Executive Vice President of Vessel Operations for Norwegian Cruise Line Holdings Ltd. Lindsay was appointed to this position in January 2015. In this role, Lindsay is responsible for Marine & Technical Operations, Hotel Operations, Entertainment, Product Development, Port & Destination Services, Fleet Personnel, Out Islands and New Build & Ship Refurbishment for all three of the company’s brands – Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises.

Prior to joining Norwegian Cruise Line Holdings Ltd., Lindsay served in a similar capacity as Executive Vice President of Vessel Operations at Prestige Cruise Holdings, the parent company of Oceania Cruises and Regent Seven Seas Cruises. Lindsay’s history with the company goes back to the inception of Oceania Cruises in 2003, where he joined as Senior Vice President, Hotel Operations and Vessel Operations. Lindsay earned his B.S. degree from Louisiana Tech University. 

In addition, several experts will also serve as senior advisors to the panel, including Dr. Caitlin Rivers, who is a faculty member and epidemiologist at the Johns Hopkins Bloomberg School of Public Health and an expert in emerging infectious disease epidemiology and outbreak science, and Dr. Phyllis Kozarsky, who is a professor emerita of medicine in the Division of Infectious Diseases at Emory University School of Medicine and an expert in pre-travel health advice and education, global health, and the epidemiology of travel related infections and infectious diseases. Dr. Kozarsky serves as an expert consultant to the Division of Global Migration and Quarantine in travelers’ health with the CDC.